Phase 2 N=22 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT) — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
Alcohol Dependence · Binge Eating
Primary: Compliance With Study Requirements: Attendance at Treatment Sessions — 5; 3 participants
Phase 2 N=12 Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue
Obesity
Primary: BAT Activity as Measured by 18F-FDG PET/CT — 0.92; 132 mL*SUVmean*g/mL — p=0.001
Phase 2 N=37 Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Diabetes Mellitus, Type 2 · Healthy
Primary: Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14) — -321.7; -256.9 (milligram / minute/…
Phase 2 N=12 Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 4 Participants
Phase 2 N=181 Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis by Five Minutes After Treatment Start at the TBS — 75.0; 75.0; 73.9; 82.5 percent of subjects achieving hemostasis
Phase 2 N=27 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma · B-Cell Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant — 19 Participants
Phase 2 N=68 Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Inflammatory Breast Cancer · Male Breast Cancer · Stage II Breast Cancer
Primary: Microscopic Pathologic CR (pCR) Rate — 27 percent of evaluable participants
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 2 N=120 Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose of Stereotactic Body Radiotherapy (SBRT) as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 — 12.0 Gy/FX
Phase 2 N=7 Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder (OCD)
Primary: Scores Change in Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS) Scores From Baseline to 230 Minutes Postinfusion. — 13.71 units on a scale
Phase 2 N=43 Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
Dumping Syndrome
Primary: Response Rate in Plasma Glucose Level — 60.5 percentage of participants
Phase 2 N=13 Effect of Baclofen on Marijuana Withdrawal and Relapse
Marijuana Dependence
Primary: Measure of Relapse: Change in Money Spent Between Baseline and Relapse Phase — 7.15; 9.77; 7.25 dollars spent on marijuana
Phase 2 N=32 Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Rectal Cancer · Adenocarcinoma of the Rectum
Primary: Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy — 100 mg
Phase 2 N=38 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Giant Cell Glioblastoma · Adult Gliosarcoma
Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs